Can-Fite BioPharma Ltd. (CANF) Net margin 2017–2025
Can-Fite BioPharma Ltd. (CANF) net profit margin by fiscal year — reported net income divided by reported revenue.
-2426.7%FY2025 · since FY2017: -613.7% → -2426.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -2426.7% | -1257.5 pp |
| FY2024 | -1169.1% | -141.7 pp |
| FY2023 | -1027.5% | +228.5 pp |
| FY2022 | -1255.9% | +223.0 pp |
| FY2021 | -1478.9% | +414.0 pp |
| FY2020 | -1892.9% | -1271.6 pp |
| FY2019 | -621.3% | -449.3 pp |
| FY2018 | -172.0% | +441.7 pp |
| FY2017 | -613.7% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CANF financial trends
CANF RevenueCANF Net incomeCANF Gross profitCANF Gross marginCANF Operating incomeCANF Operating marginCANF Operating cash flowCANF Free cash flowCANF Capital expendituresCANF Return on equityCANF Stock buybacksCANF Dividends paidCANF Total assetsCANF Total liabilitiesCANF Shareholders’ equityCANF overview →